ATXI
Avenue Therapeutics, Inc. [ATXI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATXI Stock Summary
In the News
ATXI Financial details
Company Rating
-
Market Cap
6M
Income
-11.55M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.09
Forward P/E
-
PEG
0
P/S
-
P/B
-0.17
P/C
-
P/FCF
-0.2
Quick Ratio
0.03
Current Ratio
0.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2
EPS next Y
-
EPS next Q
-
EPS this Y
-204.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-61.42%
-
-
-
-
SMA20
8.7%
SMA50
-19.35%
SMA100
-86.41%
Inst Own
-
Inst Trans
-
ROA
-1429%
ROE
439%
ROC
3.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.113-1.28
52W High
-
52W Low
-
RSI
45.61
Rel Volume
-
Avg Volume
1.68M
Volume
1.78K
Perf Week
-17.31%
Perf Month
-6.56%
Perf Quarter
-88.32%
Perf Half Y
-88.44%
-
-
-
-
Beta
-0.26
-
-
Volatility
0.03%, 0.02%
Prev Close
-24.18%
Price
0.215
Change
0%
Company Profile
- Volume Average 1.68M
- Market Capitalization 6M
- Employee 3
- CEO Dr. Alexandra MacLean M.D.
- Headquarters New York,NY,US
- IPO Date 2017-06-27
-
Website
https://www.avenuetx.com 
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
